Abstract:Purpose of reviewThis article reviews novel and emerging therapeutic agents for the treatment of inflammatory bowel disease (IBD), including biologic and small molecule drugs.Recent findingsBeyond TNF antagonist therapy, there are several newer classes of biologics targeting alternative pathways with lower immunogenicity rates and favorable safety profiles. Furthermore, the inherent limitations of biologics, mainly immunogenicity and parenteral administration, have led to renewed interest in the development of small molecule drugs.SummaryOver the last two decades, the pharmacological management of inflammatory bowel disease has transitioned from use of aminosalicylates, corticosteroids, and immunosuppressants to biologic therapy, shifting from a strategy based on controlling symptoms to a treat-to-target paradigm, to prevent disease-related complications. Although biologics have greatly improved the management of inflammatory bowel disease, many patients discontinue these therapies due to limited efficacy or adverse events. Beyond TNF antagonists, several new biologics are either approved or in late-stage development including anti-adhesion molecules as well as interleukins targeting the IL-12 and IL-23 pathways. The first approved Janus kinase (JAK) inhibitor for ulcerative colitis has been followed by the development of several others in late-stage clinical trials with greater JAK selectivity, which could translate to enhanced safety profiles. Beyond JAKs, the sphingosine phosphate inhibitors are in phase 3 trials for IBD and are a promising target as oral therapies.

Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions